Fusion processing of itraconazole solid dispersions by KinetiSol® dispersing: A comparative study to hot melt extrusion

Journal of Pharmaceutical Sciences

Volumn 99, Issue 3, 2010, Pages 1239-1253

  Dinunzio, James C ^a,c   Brough, Chris ^b   Miller, Dave A ^a,d   Williams III, Robert O ^a   McGinity, James W ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b DisperSol Technologies LLC   (United States)

^c PharmaForm LLC   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

Author keywords

Amorphous; Bioavailability; Dissolution; Hot melt extrusion; Hydroxypropyl methylcellulose; Itraconazole; Kinetisol dispersing; Solid dispersion; Thermal processing

Indexed keywords

HYDROXYPROPYLMETHYLCELLULOSE; ITRACONAZOLE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG MANUFACTURE; GLASS TRANSITION TEMPERATURE; HOT MELT EXTRUSION; NONHUMAN; PELLET EXTRUSION; RAT; SOLID DISPERSION; SOLID STATE; X RAY DIFFRACTION;

EID: 76649097298     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21893     Document Type: Article

References (45)

1. Lipinski CA. 2004. Lead- and drug-like compounds: The rule-of-five revolution. Drug Discov Today Technol 1:337-341.
2. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 46:3-26.
3. Keck CM, Müller RH. 2006. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 62:3-16.
4. Bhardwaj V, Hariharan S, Bala I, Lamprecht A, Kumar N, Panchagnula R, Kumar MNVR. 2005. Pharmaceutical aspects of polymeric nanoparticles for oral drug delivery. J Biomed Nanotechnol 1:235-258.
5. Willis RC. 2004. Good things in small packages: Nanotech advances are producing mega-results in drug delivery. Mod Drug Discov 7:30.
6. Blagden N, de Matas M, Gavan PT, York P. 2007. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Del Rev 59:617-630.
7. Gao P, Morozowich W. 2006. Development of supersaturatable self-emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs. Expert Opin Drug Deliv 3:97-110.
8. Pinnamaneni S, Das NG, Das SK. 2002. Formulation approaches for orally administered poorly soluble drugs. Die Pharmazie 57:291-299.
9. Mehnert W, Mäder K. 2001. Solid lipid nanoparticles production, characterization and applications. Adv Drug Del Rev 47:165-196.
10. Brewster ME, Vandecruys R, Peeters J, Neeskens P, Verreck G, Loftsson T. 2008. Comparative interaction of 2-hydroxypropyl-β-cyclodextrin and sulfobutylether-β-cyclodextrin with itraconazole: Phase-solubility behavior and stabilization of supersaturated drug solutions. Eur J Pharm Sci 34:94-103.
11. Loftsson T, Brewster ME. 1996. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci 85:1017-1025.
12. Breitenbach J. 2002. Melt extrusion: From process to drug delivery technology. Eur J Pharm Biopharm 54:107-117.
13. Breitenbach J. 2006. Melt extrusion can bring new benefits to HIV therapy: The example of Kaletra tablets. Am J Drug Deliv 4:61-64.
14. Kondo N, Iwao T, Hirai K, Fukuda M, Yamanouchi K, Yokoyama K, Miyaji M, Ishihara Y, Kon K, Ogawa Y, Mayumi T. 1994. Improved oral absorption of enteric coprecipitates of a poorly soluble drug. J Pharm Sci 83:566-570.
15. Breitenbach J, Mägerlin M. 2003. Melt-extruded solid dispersions. In: Ghebre-Sellassie I, Martin C, editors. Pharmaceutical extrusion technology. New York, NY: Informa Healthcare. pp. 245-260.
16. Dyar SC, Mollan M, Ghebre-Sellassie I. 2003. Melt-extruded particulate dispersions. In: Ghebre-Sellassie I, Martin C, editors. Pharmaceutical extrusion technology. New York, NY: Informa Healthcare. pp. 261-276.
17. Gilis PM, De Condé VFV, Vandecruys RPG. 1997. Beads having a core coated with an antifungal and a polymer. In: Office USPT, editor. United States Patent & Trademark Office. US Patent 5,633,015.
18. Letko E, Bhol K, Pinar V, Foster CS, Ahmed AR. 1999. Tacrolimus (FK 506). Ann Allergy Asthma Immunol 83:179-190.
19. Chiou WL, Riegelman S. 1971. Pharmaceutical applications of solid dispersions. J Pharm Sci 60: 1281-1302.
20. Vasconcelos T, Sarmento B, Costa P. 2007. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 12:1068-1075.
21. Leuner C, Dressman J. 2000. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Sci 50:47-60.
22. Verreck G, Decorte A, Heymans K, Adriaensen J, Liu D, Tomasko D, Arien A, Peeters J, Van den Mooter G, Brewster ME. 2006. Hot stage extrusion of p-amino salicylic acid with EC using CO2 as a temporary plasticizer. Int J Pharm 327:45-50.
23. Crowley MM, Zhang F, Repka MA, Thumma S, Upadhye SB, Battu SK, McGinity JW, Martin C. 2007. Pharmaceutical applications of hot-melt extrusion: Part I. Drug Dev Ind Pharm 33:909-926.
24. McGinity JW, Repka MA, Koleng JJ, Jr., Zhang F. 2007. Hot-melt extrusion technology. In: Swarbrick J, Boylan JC, editors. Encyclopedia of pharmaceutical technology. Hooboken, NJ: Informa Healthcare USA. pp. 2004-2020.
25. Repka MA, Battu SK, Upadhye SB, Thumma S, Crowley MM, Zhang F, Martin C, McGinity JW. 2007. Pharmaceutical applications of hot-melt extrusion: Part II. Drug Dev Ind Pharm 33:1043-1057.
26. Patterson JE, James MB, Forster AH, Lancaster RW, Butler JM, Rades T. 2007. Preparation of glass solutions of three poorly water soluble drugs by spray drying, melt extrusion and ball milling. Int J Pharm 336:22-34.
27. Six K, Berghmans H, Leuner C, Dressman J, Werde KV, Mullens J, Benoist L, Thimon M, Meublat L, Verreck G, Peeters J, Brewster M, Van den Mooter G. 2003. Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion, part II. Pharm Res 20:1047-1054.
28. Six K, Daems T, de Hoon J, Van Hecken A, Depre M, Bouche M-P, Prinsen P, Verreck G, Peeters J, Brewster ME, Van den Mooter G. 2005. Clinical study of solid dispersions of itraconazole prepared by hot-stage extrusion. Eur J Pharm Sci 24:179-186.
29. Verreck G, Six K, Van den Mooter G, Baert L, Peeters J, Brewster ME. 2003. Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion-Part I. Int J Pharm 251:165-174.
30. Miller DA. 2007. Improved oral absorption of poorly water-soluble drugs by advanced solid dispersion systems. Division of Pharmaceutics. Ph.D. dissertation. Austin, TX: The University of Texas at Austin. p. 312.
31. Peeters J, Neeskens P, Tollenaere JP, Van Remoortere P, Brewster ME. 2002. Characterization of the interaction of 2-hydroxypropyl-b-cyclodextrin with itraconazole at pH 2, 4 and 7. J Pharm Sci 91:1414-1422.
32. Rambali B, Verreck G, Baert L, Massart DL. 2003. Itraconazole formulation studies of the melt-extrusion process with mixture design. Drug Dev Ind Pharm 29:641-652.
33. Gordon M, Taylor JS. 1952. Ideal copolymers and the second-order transitions of synthetic rubbers. I. Noncrystalline copolymers. J Appl Chem 2:493-500.
34. Simha R, Boyer RF. 1962. On a general relation involving the glass temperature and coefficients of expansion of polymers. J Chem Phys 37:1003-1007.
35. Miller DA, DiNunzio JC, Yang W, McGinity JW, Williams RO III. 2008. Enhanced in vivo absorption of itraconazole via stabilization of supersaturation following acidic-to-neutral pH transition. Drug Dev Ind Pharm 34:890-902.
36. Miller DA, McConville JT, Yang W, Williams RO III, McGinity JW. 2007. Hot-melt extrusion for enhanced delivery of drug particles. J Pharm Sci 96:361-376.
37. Craig DQM. 2002. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm 231:131-144.
38. Matteucci ME, Brettmann BK, Rogers TL, Elder EJ, Robert O, Williams I, Johnston KP. 2007. Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media. Mol Pharm 4:782-793.
39. Serajuddin ATM. 1999. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88:1058-1066.
40. Shin JH, Choi KY, Kim YC, Lee MG. 2004. Dosedependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: Intestinal first-pass effect. Antimicrob Agents Chemother 48:1756-1762.
41. Quinney SK, Galinsky RE, Jiyamapa-Serna VA, Chen Y, Hamman MA, Hall SD, Kimura RE. 2008. Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats. Drug Metab Disposition 36:1097-1101.
42. Miller DA, DiNunzio JC, Yang W, McGinity JW, Williams RO III. 2008. Targeted intestinal delivery of supersaturated itraconazole for improved oral absorption. Pharm Res 25:1450-1459.
43. Yoo SD, Lee S-H, Kang E, Jun H, Jung J-Y, Park JW, Lee K-H. 2000. Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. Drug Dev Ind Pharm 26:27-34.
44. Jung J-Y, Yoo SD, Lee S-H, Kim K-H, Yoon D-S, Lee K-H. 1999. Enhanced solubility and dissolution rate of itraconazole by a solid dispersion technique. Int J Pharm 187:209-218.
45. DiNunzio JC, Miller DA, Yang W, McGinity JW, Williams RO III. 2008. Amorphous compositions using concentration enhancing polymers for improved bioavailability. Mol Pharm 5:968-980. DOI 10.1002/